PEPTIDE CORTEXThe library
← The library

Oxytocin

Cognition/Mood
Evidence grade
CMixed/unclear regulatory status
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeNeuroendocrine
MechanismBonding/social neuropeptide; uterotonic in obstetrics
EffectsBonding/social neuropeptide; uterotonic in obstetrics
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
FDA labelPitocin (obstetric: induction/augmentation of labour)
RouteIntravenous infusion, in hospital
FrequencyContinuous infusion titrated to uterine response
StartingInduction: 0.5-1 mU/min IV
EscalationIncrease by 1-2 mU/min at 30-60 min intervals until the desired contraction pattern
TargetDesired contraction pattern

Obstetric only; no psychiatric, social, sexual or longevity indication. Standard solution 10 units in 1,000 mL.

Clinical trialSOARS-B, autism (Sikich, NEJM 2021)
RouteIntranasal
FrequencyDaily, 24 weeks
StartingTitrated to target
EscalationNot given in the summary
Target48 IU/day total. No significant difference in social or cognitive outcomes vs placebo.
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous; intranasal
FrequencyOnce daily (SC); per session (intranasal)
StartingSC low 100 mcg once daily
EscalationSC moderate 200-300 mcg; upper 400-500 mcg once daily
TargetIntranasal 10-72 IU/session in research (24 IU commonly cited)
CycleShort 1-2 weeks; standard 4-6 weeks then 1-2 weeks off

The guide says it "does not cross blood-brain barrier meaningfully" after SC.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Serious obstetric risks if misused; do not self-administer

Obstetric medication—avoid self-use; interactions managed clinically.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.